Immunotherapy for Urothelial Carcinoma: Milestones and Future Horizons

Dear Colleagues,

Over the last decade, remarkable advances have been made in the urothelial carcinoma (UC) therapeutic landscape. Nowadays, in addition to the conventional chemotherapeutic approach, we can offer advanced UC patients immune checkpoint inhibitors (ICIs), antibody–drug conjugates (ADCs) and targeted agents (TAs). The UC immunotherapy era, which began with PD-1/PD-L1 inhibitor monotherapy, is currently evolving towards immune combinations with chemotherapy, radiotherapy and targeted agents and ICI adoption in the early disease stages. An increasing number of UC patients will receive immunotherapeutic treatments in the years to come. Therefore, the acquisition of further data from preclinical and clinical models and the detection of prognostic and predictive biomarkers will be crucial to tailoring and optimising the therapeutic strategy for the individual UC patient.

Dr. Mimma Rizzo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• urothelial carcinoma
• bladder cancer
• immunotherapy
• targeted therapies
• antibody–drug conjugate
• radiotherapy
• combination therapy
• biomarker
• prognosis
• prediction